Heidelberg-based Revier Therapeutics launches with €6 million to develop cardiometabolic therapies
Revier Therapeutics, a Heidelberg-based BioTech company advancing disease-modifying therapies for patients with cardiometabolic disease, has officially launched and announced the closing of a €6 million Seed financing round. The round was led by the KHAN Technology Transfer Fund II, with participat
<p>Revier Therapeutics, a Heidelberg-based BioTech company advancing disease-modifying therapies for patients with cardiometabolic disease, has officially launched and announced the closing of a €6 million Seed financing round. The round was led by the KHAN Technology Transfer Fund II, with participat</p>